Dermatology Drugs Global Market Report 2018

1. Dermatology Drugs Global Market Report 2018 Including: Dermatology Drugs Covering: Johnson & Johnson, Allergan Plc, Galderma S.A, Novartis AG, GlaxoSmithKline Plc Feb 2018

2. Reasons to Purchase • Outperform competitors using accurate up to date demand-side dynamics information. • Identify growth segments for investment. • Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market. • Create regional and country strategies on the basis of local data and analysis. • Stay abreast of the latest customer and market research findings • Benchmark performance against key competitors. • Develop strategies based on likely future developments. • Utilize the relationships between key data sets for superior strategizing. • Suitable for supporting your internal and external presentations with reliable high quality data and analysis • Gain a global perspective on the development of the market. • Report will be updated with the latest data and delivered to you within 3-5 working days of order. Scope Markets Covered: Dermatology Drugs Companies Mentioned: Johnson & Johnson, Allergan Plc, Galderma S.A, Novartis AG, GlaxoSmithKline Plc Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia. Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa Time series: Five years historic and forecast. Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, Dermatology Drugs Indicators Comparison. Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments. Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

3. Dermatology Drugs Dermatology Drugs Market Characteristics Characteristics Market The dermatology drugs market includes medications that are used for the treatment of skin conditions such as dermatitis (including eczema), rosacea, hyperhidrosis, androgenic alopecia, onychomycosis, hair loss, acne, immune disorders (including psoriasis), microbial infections (bacterial, fungal, and viral), vascular and pigmented lesion removal, common warts, seborrheic keratosis, and other skin diseases The market numbers within this briefing are restricted to pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing. Dermatology drugs used to treat acne include local anesthetics, cleansers, anti- inflammatory agents, anti-infectives, emollients, and astringents. These drugs are available for both topical (external) use and internal use. These drugs can be sold as over-the-counter (OTC) as well as prescription drugs. Major OTC dermatological drugs include Differin, Lamisil, Monistat, and Abreva. Some of the major dermatology prescription drugs include Clobetasol propionate, Flucinonide, Baxdela, Siliq, Rhofade. The segments that are covered include – Dermatology Drugs – Topical dermatology drugs are available in a wide range of In this report market value is defined as the revenues organizations earn by selling their goods and services within the specified market, based on the price at which they sell. Only goods and services traded between entities are included. The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.

5. Dermatology Drugs Dermatology Drugs Market Historic Growth Historic Growth Market The global dermatology drugs market grew from $X billion in 2013 to $X billion in 2017 at a compound annual growth rate (CAGR) of X%. The chart and table below shows the year-on-year growth of the global dermatology drugs market during 2013 – 2017. Drivers of the Market: Restraints on the Market:

6. Dermatology Drugs Dermatology Drugs Market Forecast Growth Forecast Growth Market The global dermatology drugs market is expected to grow from $XX billion in 2017 to $40 billion in 2021 at a compound annual growth rate (CAGR) of XX%. Going forward, increase in the number of indications treated by topical drugs coupled with increase in acne and rosacea patients will drive the market for dermatology drugs. The chart and table below shows the year-on-year growth of the global dermatology drugs market during 2017 - 2021. Drivers of the Market: Restraints on the Market:

7. Dermatology Drugs Dermatology Drugs Market Regional And Country Analysis Regional And Country Analysis Market The Asia Pacific was the largest region in the dermatology drugs market in 2017, dermatology drugs for $X billion or 38% market share. North America was the x largest region dermatology drugs for $X billion or X% market share. Western Europe was the x largest region dermatology drugs for $X billion or X% market share.

8. Dermatology Drugs Dermatology Drugs Market Competitive Landscape Competitive Landscape Market The leading competitors in the global dermatology drugs market are Johnson & Johnson, Allergan Plc, Galderma S.A., Novartis AG, GlaxoSmithKline Plc. The chart and table below displays the percentage market share of the top players in the dermatology drugs market industry. Johnson & Johnson generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Allergan Plc. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Galderma S.A. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year.

9. Novartis AG generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. GlaxoSmithKline Plc. generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Bayer AG generated revenues of $XX billion for the financial year 2016, an XX% decrease from the previous year. LEO Pharma A/S generated revenues of $XX billion for the financial year 2016, an XX% increase from the previous year. Company Profile Johnson & Johnson Overview Johnson & Johnson (J&J) was the largest competitor in the dermatology drugs market in 2017 with a XX% share of the market. The company is engaged in the development, manufacturing and marketing of personal care hygienic products, pharmaceuticals and surgical equipment. J&J was founded in 1886 and is headquartered at New Jersey, USA. Products and Services J&J operates through the following business divisions – The Consumer division offers The Pharmaceutical division offers products in The Medical Devices And Diagnostics division manufactures products used by Strategy Johnson & Johnson aims to grow its geographic footprint and increase investments in emerging markets and developed markets such as Japan. In 2016, the company spent $9.1 billion in R&D.liv With prioritized investments in internal R&D, strategic licensing arrangements, partnerships and select acquisitions, the company intends to build a robust product pipeline for

10. Financial Performance Johnson & Johnson’s Beauty section in Consumer division, involved in dermatology drugs manufacturing, generated revenues of $3.9 billion for the financial year 2016, a 7.3% increase from the previous year. The company had market Allergan Plc Overview Products and Services Strategy Financial Performance Galderma S.A Overview Products and Services Strategy Financial Performance Novartis AG Overview Products and Services Strategy Financial Performance GlaxoSmithKline Plc Overview Products and Services Strategy Financial Performance